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Abstract
Importance: Previous studies report both coexistence and mutual exclu-
sivity of atopic eczema (AE) and psoriasis, but these have not been
appraised systematically. Knowledge of such disease association throws
light on disease mechanisms and may influence therapeutic choices.
Objective: To summarise evidence for AE and psoriasis occurring in the
same person at the same point in time. Planned primary outcome was the
incidence, prevalence or risk of psoriasis or eczema.
Methods: Ovid MEDLINE and Ovid Embase were searched from inception
to 1st February 2020. The search strategy was built around the key terms
‘atopic eczema’, ‘psoriasis’ and ‘co‐existence’. Observational studies (cohort,
case‐control, cross‐sectional and case‐series) with a minimum of 10
consecutive patients were included. There were no restrictions on partici-
pants, geography or language. Studies were selected, data extracted and
critically appraised by two independent reviewers. Data were extracted on
the method of diagnosis: health professional (dermatologist, criteria, other),
self‐reported, not specified. Study quality was assessed using validated
Joanna Brigg's Institute critical appraisal tools. A random‐effects model was
used to combine studies. The effect of study quality on the pooled estimate
was investigated using stratification. Heterogeneity was explored by sub-
group analysis.
Results: This review included 31 studies and 20 523 individuals with pso-
riasis and 1 405 911 with AE. Eight studies reported the prevalence of AE in
those with psoriasis and values ranged from 0.17% to 20%: the pooled
prevalence was 2% (95% confidence interval [CI]: 1, 3). Seven studies re-
ported the prevalence of psoriasis in those with AE and values ranged from
0.3% to 12.6%; the pooled prevalence was 2% (95% CI: 1, 3). Ten studies
were assessed as low risk of bias. Geographical area, method of diagnosis,
setting and whether the assessment of diagnosis was blinded, partly
contributed to the heterogeneity.
Conclusions: This review provides some evidence for the coexistence of AE
and psoriasis. Clinicians should be aware of coexistence at diagnosis, when
selecting therapies and when reviewing poor response to treatment.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, pro-
vided the original work is properly cited.
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1 | INTRODUCTION
Atopic eczema (also known as atopic dermatitis or just
eczema) and psoriasis are both common chronic, in-
flammatory diseases affecting the skin, with large var-
iations in their incidence and prevalence between
countries.1–3 The individual, societal and healthcare
costs of both diseases are significant. Eczema and
psoriasis can affect people of any age, localise to high
impact sites (e.g., hands), involve large areas of the
body, effect psychosocial well‐being and have a nega-
tive impact on quality of life especially with coexistent
comorbidities.4,5 Management of both diseases is
therefore part of routine practice and the focus of
highly specialised clinics.
Eczema and psoriasis are primarily diagnosed by a
healthcare professional after a clinical examination.
Diagnostic criteria for eczema, but not psoriasis, have
been validated and are widely used in clinical
research.6,7 It has been argued that eczema andpsoriasis
cannot coexist in the same person because this requires
the activation of opposing inflammatory pathways (Th2
vs. Th1).8,9 To date, observational studies have sup-
ported both coexistence and mutual exclusivity of
eczema and psoriasis, and also reported conflicting re-
lationships between other Th2 and Th1 diseases.10–12
This systematic review aims to reconcile these
divergent results through collectively presenting the
spectrum of evidence and providing pooled values with
greater precision than individual smaller studies. In the
review we will explore the effect of important differ-
ences between studies (population, study design, study
quality) on the results. We intend that new summative
data on the coexistence of eczema and psoriasis will
give important clinical or population level insight into
the immunopathogenesis of both diseases. These data
may inform the development and choice of targeted
biologic treatments and may challenge how we clini-
cally categorise disease.
The primary objective of this systematic review and
meta‐analysis is to investigate the incidence, preva-
lence or risk of eczema and psoriasis occurring in the
same individual at the same point in time.
2 | METHODS
2.1 | Protocol
The review protocol is available on PROSPERO https://
www.crd.york.ac.uk/prospero/display_record.php?Record
ID=118343.
2.2 | Objectives of the review
The primary objective for the review was to investigate
the prevalence, incidence or risk (relative risk or odds
ratio [OR]) of eczema and psoriasis occurring in the
same individual at the same time point. The secondary
objective was to investigate the same at any time point.
A tertiary objective was to summarise the immunologic
and genetic data on coexistence.
2.3 | Search strategy and reference
searching
OVID MEDLINE and OVID Embase were searched
from inception on 1st February 2020. A search strategy
was built with an information specialist (D.G.) around
the key terms ‘atopic eczema’, ‘psoriasis’ and ‘co‐exis-
tence’ using medical subject headings and free text
words (Supporting Information 1). Reference lists of
included studies were hand‐searched. Studies with a
primary objective matching the review question were
also included in prospective citation searching using
Google Scholar. Authors of included studies were
emailed to help identify any published or unpublished
data on the review question.
2.4 | Inclusion and exclusion criteria
Observational studies (cohort, case‐control, cross‐
sectional and case‐series of at least 10 consecutive
What is already known about this
topic?
� Atopic eczema and psoriasis are two of the
most common skin diseases and are managed
in primary, secondary and tertiary care.
� Observational studies have supported both
coexistence and mutual exclusivity of atopic
eczema and psoriasis.
� Studies also conflict on the coexistence of
other Th1 and Th2 diseases.
What does this study add?
� There is some evidence that atopic eczema
and psoriasis may present in the same indi-
vidual, both simultaneously and
consecutively.
� Coexistence of disease may occur at a level
equal or lower than expected.
� Clinicians should be aware of coexistence at
diagnosis, when selecting therapies and when
reviewing poor response to treatment.
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patients to give sufficient data) were included. Studies
were required to provide incidence, prevalence or risk
data on the coexistence of psoriasis and eczema.
Cohort studies were included to provide data on
coexistence in the same time period, consecutive onset
and incidence estimates.
There were no restrictions on the age, gender,
ethnicity, setting or geographical location of partici-
pants. Studies of all languages for which a translator
was available were included in the review. The review
investigated two separate populations: (i) the diagnosis
of eczema (outcome) in a psoriasis population (expo-
sure); (ii) the diagnosis of psoriasis (outcome) in an
eczema population (exposure). The diseases of interest,
eczema and psoriasis, were defined and recorded as a
diagnosis made by a health professional (clinical diag-
nosis), self‐reported or the method of diagnosis was
unspecified. The category of diagnosis made by a health
professional was further divided into whether it was
made by a dermatologist or nondermatologist, and if
diagnostic criteria were used. The definition of psoria-
sis included all subtypes of psoriasis. The term atopic
eczema has been used interchangeably with eczema/
dermatitis and studies were excluded if they specif-
ically focused on nonatopic eczema (e.g., irritant,
allergic, venous, nummular). Conference abstracts were
included if they contained sufficient information on the
primary objective.
2.5 | Study screening and eligibility
assessment
Titles and abstracts were screened independently by
two authors (A.C., U.A. or E.B.T.) using Rayyan QCRI
(https://rayyan.qcri.org/). Full text eligibility was inde-
pendently assessed by two authors (A.C., U.A. or EBT)
and any differences were discussed with a third author
(E.B.T. or S.G).
2.6 | Data extraction
Two authors (A.C., U.A., E.B.T. or S.J.L.) independently
completed the data extraction from included studies. A
data extraction pro‐forma was piloted on five studies
(Supporting Information 2). Timing of outcome was
categorised as at the same time point (simultaneous
disease), any time point (lifetime or study duration
coexistence) or timing unclear. Where prevalence data
were missing, study authors were contacted for further
details.
2.7 | Quality assessment
Included studies were critically appraised by two in-
dependent authors (A.C., U.A., E.B.T. or S.J.L.) using
validated Joanna Briggs Institute critical appraisal
quality assessment tools for each study type.13 The
number of appraisal questions for each study type
differed and therefore a percentage of criteria indi-
cating low risk of bias was calculated; ≥70% was
required for studies to be classified as low risk of bias.
An additional quality assessment question was added
by the review team post‐hoc to assess whether the
outcome diagnosis of eczema and/or psoriasis was
made blinded to the review question. We felt this was
an important potential source of information bias,
because knowledge of the research question may have
influenced whether a diagnosis of coexistent eczema
and psoriasis was made or not.
2.8 | Data analysis
All extracted data were included in a narrative syn-
thesis. A meta‐analysis for the primary and secondary
objectives was planned if there were sufficient clinically
similar studies providing frequency/association data.
Meta‐analysis was only possible for prevalence data
because there were insufficient data on incidence and
risk; pooled data have been presented as forest plots
with 95% confidence intervals (CIs). A random effects
model (DerSimonian and Laird) was used and hetero-
geneity assessed statistically using standard Chi‐
squared (I2). Heterogeneity was explored by planned
subgroup analysis (setting, geographical area, method
of diagnosis, age of participant, risk of bias). Stata v14.0
was used for the meta‐analysis. Assessment of publi-
cation bias using Egger's test was planned, but not
possible because there were less than 10 studies in
each meta‐analysis.
3 | RESULTS
The electronic database search identified 4783 cita-
tions. An additional 20 studies were identified through
retrospective and prospective citation searching. No
studies were identified by direct contact with study
authors (three authors responded). After deduplication
3586 studies remained. Fifty‐one full text articles were
assessed for eligibility and 31 were included in the
review.10–12,14–41 This included four conference
abstracts.19,22,24,33 The PRISMA flow diagram is pre-
sented in Figure 1 and excluded studies in Supporting
Information 3.
The characteristics of each included study are pre-
sented in Tables 1 and 2. In total, there were 25 cross‐
sectional studies, three cohort and three case series. All
studies were conducted between 1989 and 2020.
Nineteen were conducted in Europe, four in the United
States of America, four in Asia, three in the Middle East
and one in Africa. Twenty‐one were hospital‐based
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studies, nine were population‐based studies and one
was conducted in schools.
The total number of individuals in the psoriatic
exposure population were 20 523 (range: 52–3837,
median: 306) and in the eczema exposure population
were 1 405 911 (range: 37–1 393 570, median: 354).
3.1 | Primary objective
3.1.1 | Prevalence of eczema in psoriasis
studies
Eight studies reported the prevalence of eczema in a
psoriasis population, where the diseases occurred at
the same time point. The main results for each study
are presented in Table 1. The prevalence ranged
from 0.17%10 to 20%.15 The pooled prevalence esti-
mate of eczema in those with psoriasis at the same
time point was 2% (95% CI: 1, 3) (Figure 2). There
was evidence of high statistical heterogeneity be-
tween the eight studies (I2 = 93.4%). Forest plots
exploring heterogeneity are presented in Figure 2
and Supporting Information 4. Geographical area and
method of diagnosis may help explain the observed
heterogeneity for the pooled prevalence of eczema in
those with psoriasis; a higher pooled prevalence was
observed in Europe (2%, 95% CI: 1, 4%) and when a
diagnosis was made by a dermatologist/using diag-
nostic criteria (3%, 95% CI: 1, 5). However, these
results were heavily influenced by Abramovits et al.15
a small cross‐sectional study of 100 patients with
psoriasis.
Only two studies were rated as low risk of bias, and
only one of these provided data where the outcome
diagnosis (eczema) was made blinded to the research
question.10 Henseler et al.10 used mostly prospectively
collected data from a large secondary care database of
42 461 patients at one dermatology department. Di-
agnoses were made by a minimum of two experienced
F I GUR E 1 PRISMA flow diagram of included studies
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dermatologists. The study aimed to investigate the
coexistence of psoriasis and more than 50 other skin
diseases, and the diagnoses were made blinded to the
study question. Beer et al.12 examined 983 consecutive
patients attending the dermatology department. The
diagnoses were made by one consultant dermatologist
who was leading the study investigating the coexis-
tence of eczema and psoriasis. There was a large dif-
ference between the prevalence values of these two
studies (0.17% vs. 7.2%), indicating that when the
outcome diagnosis was made by a clinician who was
looking for coexistent disease the prevalence values
are higher (Figure 2).
3.1.2 | Prevalence of psoriasis in eczema
populations
Seven studies reported the prevalence of psoriasis in
an eczema population, where the diseases occurred at
the same time point. The main results from each study
are presented in Table 2. The prevalence ranged from
0.3%18 to 12.6%.12 The pooled prevalence estimate of
psoriasis in those with eczema at the same time point
was 2% (95% CI: 1, 3) (Figure 3). There was evidence of
high statistical heterogeneity between the seven
studies (I2 = 90.53%). Forest plots exploring hetero-
geneity are presented in Figure 3 and Supporting
F I GUR E 2 Forest plots of the prevalence of eczema in individuals with psoriasis at one time point. All studies (a), and stratified for
geographical area (b), method of diagnosis (c), low risk of bias and blinding (d). Proportion of 0.1 represents a prevalence of 10%
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Information 4. There is evidence that setting may help
explain the observed heterogeneity. Heterogeneity
remained high between the hospital‐based studies
(I2 = 92.60%) but was greatly reduced between the
population‐based studies (Figure 3).
Five studies were rated as low risk of bias, and four
provided data where the outcome diagnosis (psoriasis)
was made blinded to the research question.10,34,39,40
These four studies include Beer et al. and Henseler
et al.10,12 Williams et al.39 conducted a cohort study of
9263 children using data from the National Child
Development Survey 1958. Diagnoses were made by
medical officers, blinded to the research question being
posed many years later. Zander et al.40 included data
from 118 939 individuals included in standardised
occupational skin examinations by trained dermatolo-
gists. These diagnoses were made blinded to the
research question of the study. Simpson et al.34
included 7035 with eczema in a cross‐sectional study
using electronic primary care records and found the
relative risk of psoriasis in the eczema population to be
2.88 (95% CI: 2.38, 3.45). Definitive doctor diagnoses
were recorded as codes before the conduct of this
study. Similar to the findings in psoriasis patients, the
pooled prevalence of psoriasis in those with eczema
was lower in studies where the diagnosis was made
F I G U R E 2 (Continued)
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blinded to the research question (1% vs. 13%)
(Figure 3).
3.2 | Secondary objective
The secondary objective investigated coexistence at
any time point. Seventeen studies reported the preva-
lence of eczema in a psoriasis population at any time
point. The main results for each study are provided in
Table 1. The pooled prevalence of eczema in those with
psoriasis at any time point was 9% (95% CI: 7, 10)
(Figure 4). Ten studies reported the prevalence of
psoriasis in an eczema population. The main results for
each study are presented in Table 2.The pooled
prevalence of psoriasis in those with eczema at any
time point was 4% (95% CI: 3, 5) (Figure 4).
One study reported the odds and two studies re-
ported the relative risk of eczema coexisting in a pso-
riasis population compared to the general population.
Galili et al.24 found the adjusted OR of eczema in those
with psoriasis to be 1.75 (95%CI 1.29, 2.37).24 Landg-
ren et al. and Naldi et al. reported the relative risk of
eczema in those with psoriasis to be 0.4 (95%CI 0.30,
0.55)11 and 5.5 (95%CI 3.0, 10.1)30 respectively. Both
studies were rated as low risk of bias and the outcome
diagnosis was made blinded, but included different
populations, military conscripts versus children.
Two studies reported the odds and one study re-
ported the relative risk of psoriasis coexisting in an
F I GUR E 3 Forest plots of the prevalence of psoriasis in individuals with eczema at one time point. All studies (a), and stratified for setting
(b) and low risk of bias and blinding (c). Proportion of 0.1 represents a prevalence of 10%
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eczema population compared to the general popula-
tion. Zander et al. reported an adjusted OR: 0.61 (95%
CI: 0.39, 0.94) and Kim et al.27 an OR 4.8 (n = 2042).
The relative risk was reported as 1.41 (95% CI: 0.58,
3.46) by Williams et al.39 The two studies reporting a
smaller association, Zander et al. and Williams et al.
were both rated low risk of bias and the outcome
diagnosis was made blinded.
3.3 | Tertiary objective
Stepanova et al.35 reported immunological and genetic
findings on the study population. Of individuals with a
‘mixed form’ of eczema and psoriasis, 42.5% (34/80)
had an elevated total immunoglobulin E (IgE) of over
120 kU/L and females demonstrated homozygosity of
the region between human leucocyte antigen B (HLA‐
B) and DRB1: DRB4 (DR53). Welp et al.38 also reported
laboratory findings. Of those with coexistent disease,
89% (16/18) of the patients showed a total IgE level of
over 120 IU/ml and there was a significant increase in
HLA‐Cw6 in 50% (9/18) patients, while HLA‐B7 and
HLA‐B17 were only found in 11% (2/18) patients.
4 | DISCUSSION
4.1 | Main findings
This review provides some evidence for the coexis-
tence of atopic eczema and psoriasis, and no convincing
evidence for the complete mutual exclusivity of both
diseases. The pooled prevalence results for both pop-
ulations were 2%, indicating coexistence of disease may
occur at a level equal or lower than expected. There
were seven studies rated low risk of bias where the
outcome diagnosis was made blinded to the research
question, but the findings from these studies are not
consistent. Prevalence at one time point may be lower
than expected (0.17% for eczema in those with psori-
asis and 1% for psoriasis in those with eczema),10,39,40
but the relative risk for psoriasis occurring in those
with atopic eczema was estimated to be 2.88.34 At any
time point, results for the relative occurrence of atopic
eczema in those with psoriasis and psoriasis in those
with atopic eczema were conflicting, RR = 0.4 and
RR = 5.511,30 and 0.61 and 1.41,39,40 respectively.
4.2 | Existing literature
There is both immunological and genetic reasoning for
why coexistence could be biologically plausible. His-
torically, it was proposed that eczema and psoriasis are
driven by opposing T‐cell activation pathways.42
However, the activation of Th2 and Th1 cells is likely to
be antigen specific and not related to the immune
system as a whole.34 Studies have indicated that acti-
vation of specific T‐cell pathways and cytokines may
not be exclusive to each disease. Th17 and Th22 are
typically associated with psoriasis, but have been found
to have a comparatively smaller role in chronic
eczema.43 In both diseases, they stimulate a keratino-
cyte response and epidermal thickening. This immu-
nological crossover may be more common in children
F I G U R E 3 (Continued)
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and certain disease phenotypes such as Asian atopic
dermatitis.44
Genetically, there has been shown to be an overlap
in the susceptibility foci, genetic pathways and genomic
regulatory sites in allergic and autoimmune disease.45
For example, chromosomes 1q21, 17q25 and 20p loci
identified in the UK genome screen for eczema coincide
with genes which are associated with psoriasis.46 The
area of the most overlap on chromosome 1q21 is the
region which overlies the epidermal differentiation
complex. Additionally, a study in this review, Stepanova
et al.35 found evidence of homozygosity in the region
between HLA‐B and HLA‐DRB1: DRB4 (DR53), this
area determines HLA class III characteristics such as
tumour necrosis factor‐α and β22 and certain comple-
ment factors which are involved in both diseases.35
4.3 | Strengths and limitations
One of the strengths of this review is the large total
sample size of over 1.4 million individuals with eczema
and psoriasis. The review includes studies published in
English, German and French, but most studies included
F I GUR E 4 a) Forest plot of the prevalence of eczema in individuals with psoriasis at any time point. (b) Forest plot of the prevalence of
psoriasis in individuals with eczema at any time point. Proportion of 0.1 represents a prevalence of 10%
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populations from North America and Western Europe,
potentially limiting the generalisability of the findings
to multiple ethnic groups. In the critical appraisal of
each study, the review team agreed that a study could
be defined as low risk of bias if it scored 70% or above.
This threshold is arbitrary and affects which studies
were included in the sensitivity analyses.
The conclusions of the review are limited by studies
identified. There were important differences between
studies, for example data source and methodology, and
this led to high heterogeneity in the meta‐analyses. The
observed heterogeneity for the pooled prevalence of
eczema in those with psoriasis were heavily influenced
by Abramovits et al.,15 a small cross‐sectional study of
100 patients with psoriasis. Despite looking at sub-
groups of studies, it was difficult to provide useful
pooled values, often with sparse data or still notably
different results for studies within the same strata.
Included studies used both existing data (retro-
spective) from departmental and national databases,
and purposefully collected prospective data mostly
from hospital dermatology departments. Both types of
data have advantages and disadvantages. The
recording of diagnoses in retrospective sources may
have considered the diagnoses to be mutually exclu-
sive, whereas unless there was blinding of the assess-
ment, prospective collection could have been biased by
the known aims of the study: leading to under or over
reporting of coexistence. We have shown that the
prevalence of coexistence was reported lower in
studies where the outcome diagnosis was made blinded
to the research question.
There were many studies with a high risk of bias
(n = 21). A key critical appraisal point, and vital for
the interpretation of the study, was specifying how
the diagnoses was made in a valid and reliable way.
We did not make assumptions if this information was
not clear. Studies which used validated diagnostic
criteria, or a dermatologist's diagnosis detailing
criteria if no others available, provided higher quality
evidence. This was more likely to occur in studies
based in hospital dermatology departments. The val-
idity of diagnoses in national databases were chal-
lenging to critically appraise and we relied on authors
specifying that the diagnostic codes had been
validated.
Included studies also mostly reported prevalence
data and did not compare to a control group. The
absence of a baseline comparator limits the interpre-
tation of the data because population prevalence of
both eczema and psoriasis differs depending on age,
geographical area and setting.
The division between eczema and psoriasis may not
be absolute and there is a growing body of research
into ‘mixed disease’, challenging how eczema and pso-
riasis are categorised into distinct entities. It may also
be argued that the data to support coexistence
represents misdiagnosis, especially when existing data
sources are used, however this does not explain the
coexistence results from prospective studies assessing
for simultaneous disease.
4.4 | Implications
Clinicians should be aware that there is evidence for
the coexistence of atopic eczema and psoriasis and be
receptive to the emergence of new and evolving skin
changes; potentially re‐evaluating and adding a second
diagnosis of a common disease. If coexistence is iden-
tified, and the skin involvement is not controlled, this
may alter the therapeutic approach. At a simple level
this may include using vitamin D analogues or tar
products if there is evidence of psoriasis in a patient
previously diagnosed with eczema. Identifying coexis-
tence may help direct the choice of therapies to one's
that have efficacy in both diseases, for example the use
of light therapy or methotrexate, or newer Janus kinase
inhibitors. When using biologic therapies, it may also be
useful to consider the effect these might have on
differing immunological pathways for patients with
coexistent diseases.
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